Joseph Romanelli, President, Human Health Int'l at Merck & Co Inc (MRK, Financial), executed a sale of 1,000 shares in the company on February 13, 2024, according to a recent SEC Filing.
Merck & Co Inc is a global healthcare company that provides prescription medicines, vaccines, biologic therapies, and animal health products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company's primary focus is on products that improve health and well-being.
Over the past year, the insider has sold a total of 6,124 shares and purchased a total of 409 shares. The recent transaction reflects a continuation of this selling trend.
The insider transaction history for Merck & Co Inc indicates a pattern of insider sales over the past year, with 18 recorded insider sells and only 1 insider buy.
On the day of the insider's recent sale, shares of Merck & Co Inc were trading at $124.89, giving the company a market capitalization of $318,830.785 billion.
The stock's price-earnings ratio stands at 898.71, significantly above both the industry median of 22.29 and the company's historical median price-earnings ratio.
With the current share price at $124.89 and a GuruFocus Value of $107.80, Merck & Co Inc's price-to-GF-Value ratio is 1.16, indicating that the stock is considered Modestly Overvalued according to GuruFocus's valuation.
The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
